Predicting Elevated Postvoid Residual Urine Volume Following <scp>OnabotulinumtoxinA</scp> Treatment for Overactive Bladder: A Pilot Study
Patients who are older, have high pretreatment PVR values, and have lower pretreatment urine flow indexes and flows may be at increased risk of developing elevated PVR after receiving onabotulinumtoxinA treatment for OAB.
Authors
- Marc Schwartz
- Kevin Cline
- Israel Franco (ORCID: https://orcid.org/0000-0002-5675-873X)
- Anand Patel (ORCID: https://orcid.org/0000-0001-9543-9267)
- David B. Glazier
Institutions
- Yale University (US)
- Urology of Virginia (US)
- Allergan (United Kingdom) (GB)
- Regional Urology (US)
- AbbVie (United Kingdom) (GB)
Publication Details
- Journal
- LUTS Lower Urinary Tract Symptoms
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1111/luts.70004
- Citations
- 1
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 1.84
Funders
- AbbVie
- Allergan